99 related articles for article (PubMed ID: 2531668)
21. [Changes in the human testis during anti-androgen treatment: histological, morphological and enzyme-histochemical investigations on testicular biopsies].
Städtler F; Horn HJ
Dtsch Med Wochenschr; 1973 May; 98(20):1013-9. PubMed ID: 4707647
[TBL] [Abstract][Full Text] [Related]
22. Sertoli cells and Leydig cells in man.
Schulze C
Adv Anat Embryol Cell Biol; 1984; 88():1-104. PubMed ID: 6150604
[No Abstract] [Full Text] [Related]
23. Histological characteristics of the human testis after long-term treatment with cyproterone acetate.
Re M; Micali F; Santoro L; Cuomo M; Racheli T; Scapellato F; Iannitelli M
Arch Androl; 1979 Nov; 3(3):263-8. PubMed ID: 518209
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma.
Klign JG; de Voogt HJ; Schröder FH; de Jong FH
Lancet; 1985 Aug; 2(8453):493. PubMed ID: 2863504
[No Abstract] [Full Text] [Related]
25. Leydig cell micronodules are a common finding in testicular biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio.
Holm M; Rajpert-De Meyts E; Andersson AM; Skakkebaek NE
J Pathol; 2003 Mar; 199(3):378-86. PubMed ID: 12579540
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
27. Gonadal function in men with testicular cancer.
Petersen PM; Giwercman A; Skakkebaek NE; Rørth M
Semin Oncol; 1998 Apr; 25(2):224-33. PubMed ID: 9562456
[TBL] [Abstract][Full Text] [Related]
28. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
Boccon-Gibod L; Laudat MH; Dugue MA; Steg A
Eur Urol; 1986; 12(6):400-2. PubMed ID: 2949980
[TBL] [Abstract][Full Text] [Related]
29. [Ultrastructural aspect of the guinea pig testicle treated with cyproterone acetate].
Bondi C; Farnesi RM; Marinelli M; Tei S; Vagnetti D
Arch Ital Anat Embriol; 1981; 86(4):385-97. PubMed ID: 6215906
[No Abstract] [Full Text] [Related]
30. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
[TBL] [Abstract][Full Text] [Related]
31. Combination treatment in M1 prostate cancer.
Ferrari P; Castagnetti G; Ferrari G; Pollastri CA; Tavoni F; Dotti A
Cancer; 1993 Dec; 72(12 Suppl):3880-5. PubMed ID: 8252509
[TBL] [Abstract][Full Text] [Related]
32. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
de Voogt HJ; Klijn JG; Studer U; Schröder F; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):965-9. PubMed ID: 2149509
[TBL] [Abstract][Full Text] [Related]
33. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Klijn JG; de Voogt HJ; Studer UE; Schröder FH; Sylvester R; De Pauw M
Cancer; 1993 Dec; 72(12 Suppl):3858-62. PubMed ID: 8252504
[TBL] [Abstract][Full Text] [Related]
34. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
[TBL] [Abstract][Full Text] [Related]
35. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
[TBL] [Abstract][Full Text] [Related]
36. Luteinizing hormone receptor-mediated effects on initiation of spermatogenesis in gonadotropin-deficient (hpg) mice are replicated by testosterone.
Spaliviero JA; Jimenez M; Allan CM; Handelsman DJ
Biol Reprod; 2004 Jan; 70(1):32-8. PubMed ID: 12954730
[TBL] [Abstract][Full Text] [Related]
37. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer.
Lopez M; Natali M; Di Lauro L; Vici P; Pignatti F; Carpano S
Cancer; 1993 Jul; 72(2):502-5. PubMed ID: 8319180
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
[TBL] [Abstract][Full Text] [Related]
39. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
Di Silverio F; Serio M; Costantini A
J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
[No Abstract] [Full Text] [Related]
40. [Therapy with LHRH analogs in a 41-year-old patient with metastatic breast cancer].
Hartmann A; Mann K
Internist (Berl); 1989 Apr; 30(4):254-7. PubMed ID: 2525538
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
